1 week Ago By ABMN Staff
Crossmark Global Holdings Inc. lessened its stake in shares of Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 4,925 shares of the specialty pharmaceutical company’s stock after selling 158 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Jazz Pharmaceuticals were worth $607,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in JAZZ. MassMutual Private Wealth & Trust FSB grew its holdings in Jazz Pharmaceuticals by 26,389.6% in the 4th quarter.
MassMutual Private Wealth & Trust FSB now owns 17,748 shares of the specialty pharmaceutical company’s stock worth $2,186,000 after acquiring an additional 17,681 shares during the last quarter. UMB Bank n.a.
boosted its holdings in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.
a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the period. Ellsworth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 0.
4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after purchasing an additional 149 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $301,000.
Finally, Kera Capital Partners Inc. bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $288,000. Institutional investors own 89.
14% of the company’s stock. Wall Street Analyst Weigh In Several equities analysts have recently issued reports on the company. TD Cowen reduced their target price on Jazz Pharmaceuticals from $200.
00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $200.
00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th.
Needham & Company LLC restated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.
00 to $175.00 in a report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock.
According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $177.00. Jazz Pharmaceuticals Stock Performance Shares of JAZZ stock opened at $122.
04 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.
74 and a current ratio of 4.26. The company has a market capitalization of $7.
38 billion, a price-to-earnings ratio of 17.19, a price-to-earnings-growth ratio of 0.87 and a beta of 0.
56. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.
17. The company’s 50-day moving average is $122.37 and its 200 day moving average is $115.
36. Insider Buying and Selling at Jazz Pharmaceuticals In other news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th.
The shares were sold at an average price of $123.41, for a total transaction of $456,617.00.
Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.
07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link . Also, CEO Bruce C.
Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.
00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84.
The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
In the last three months, insiders have sold 8,253 shares of company stock worth $1,001,434. Insiders own 4.20% of the company’s stock.
Jazz Pharmaceuticals Profile ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Featured Articles Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ). Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
